Premium
Autoimmune thyroid disease following alemtuzumab therapy and hematopoietic cell transplantation in pediatric patients with sickle cell disease
Author(s) -
Williams Kristen M.,
Dietzen Danielle,
Hassoun Abeer A.,
Fennoy Ilene,
Bhatia Monica
Publication year - 2014
Publication title -
pediatric blood and cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.116
H-Index - 105
eISSN - 1545-5017
pISSN - 1545-5009
DOI - 10.1002/pbc.25102
Subject(s) - alemtuzumab , medicine , cd52 , hematopoietic stem cell transplantation , disease , transplantation , immunology
Allogenic hematopoietic cell transplantation (alloHCT) is currently the only curative treatment option for patients with sickle cell disease. Alemtuzumab is a monoclonal antibody directed against CD52 positive cells used in myeloablative conditioning regimens for alloHCT. Its use has been associated with development of autoimmune disease in adult patients with rheumatologic conditions. We report on three cases of new onset autoimmune thyroid disease after alloHCT treatment with alemtuzumab in pediatric patients with sickle cell disease. Pediatr Blood Cancer 2014;61:2307–2309. © 2014 Wiley Periodicals, Inc.